tiprankstipranks
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksStock ScreenerCompare StocksPenny Stock ScreenerTop Product Insights Stocks
Daily Updates
Daily Analyst RatingsTrending StocksTop Stock GainersTop Stock LosersMost Active StocksDividend StocksChatGPT Stocks
New
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarMarket Holidays
ETF Research Tools
ETF CenterETF Screener
New
Compare ETFsTop ETFs by AUM
ETFs On the Move
Top ETF GainersTop ETF LosersMost Active ETFs
ETF Ideas
S&P 500 Index ETFsNasdaq 100 Index ETFsS&P 500 Sector ETFsBond ETFsCommodity ETFsCurrency ETFsIndustry ETFs
Best Dividend StocksBest High Yield Dividend StocksDividend Stock ComparisonDividend Calculator
Popular
Dividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
My PortfolioMy WatchlistMy PerformanceMy Portfolio AnalysisCrowd Insights
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
Education
TipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityCareersContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stock Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Stock Screener
Compare Stocks
Penny Stock Screener
Top Product Insights Stocks
Daily Updates
Daily Analyst Ratings
Trending Stocks
Top Stock Gainers
Top Stock Losers
Most Active Stocks
Dividend Stocks
ChatGPT Stocks
New
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Market Holidays
ETF Research Tools
ETF Center
ETF Screener
New
Compare ETFs
Top ETFs by AUM
ETFs On the Move
Top ETF Gainers
Top ETF Losers
Most Active ETFs
ETF Ideas
S&P 500 Index ETFs
Nasdaq 100 Index ETFs
S&P 500 Sector ETFs
Bond ETFs
Commodity ETFs
Currency ETFs
Industry ETFs
Best Dividend Stocks
Best High Yield Dividend Stocks
Dividend Stock Comparison
Dividend Calculator
Popular
Dividend Returns Comparison
Dividend Calendar
Crypto Center
Bitcoin
Ethereum
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
My Portfolio
My Watchlist
My Performance
My Portfolio Analysis
Crowd Insights
Newsletter Center
Stock Market News
Stock Analysis & Ideas
Popular
ETF News
Global Markets News
Expert Spotlight
TipRanks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
Education
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Careers
Contact Us
Working with TipRanks
Enterprise Solutions
Best Online Brokers
Become an Affiliate
Follow Us
Plans & Pricing

ABUS Stock Latest News

Arbutus to Present at JMP Securities Life Sciences Conference
Press ReleasesArbutus to Present at JMP Securities Life Sciences Conference
18d ago
ABUS
Arbutus Reports First Quarter 2023 Financial Results and Corporate Update
Press ReleasesArbutus Reports First Quarter 2023 Financial Results and Corporate Update
23d ago
ABUS
Arbutus Biopharma (ABUS) Q1 Earnings Cheat Sheet
Pre-EarningsArbutus Biopharma (ABUS) Q1 Earnings Cheat Sheet
25d ago
ABUS
Arbutus Biopharma announces clinical data for AB-729 trial
The FlyArbutus Biopharma announces clinical data for AB-729 trial
30d ago
ABUS
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
Press ReleasesArbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
1M ago
ABUS
Arbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
Press ReleasesArbutus Announces FDA Clinical Hold on IND Application for AB-101, an oral PD-L1 inhibitor
1M ago
ABUS
Arbutus Biopharma announces FDA clinical hold on IND for AB-101
The FlyArbutus Biopharma announces FDA clinical hold on IND for AB-101
1M ago
ABUS
Arbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
Press ReleasesArbutus to Report First Quarter 2023 Financial Results and Provide Corporate Update
1M ago
ABUS
Arbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
Press ReleasesArbutus to Present AB-729 and AB-161 Data at the Global Hepatitis Summit 2023
1M ago
ABUS
Arbutus, Genevant file patent infringement suit against Pfizer, BioNTech
The FlyArbutus, Genevant file patent infringement suit against Pfizer, BioNTech
2M ago
PFE
ABUS
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
Press ReleasesArbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
2M ago
ABUS
Arbutus Biopharma doses first subject in Phase 1 trial with AB-161
The FlyArbutus Biopharma doses first subject in Phase 1 trial with AB-161
2M ago
ABUS
Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
Press ReleasesArbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161
2M ago
ABUS
Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
Press ReleasesArbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research
2M ago
ABUS
Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
Press ReleasesArbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update
3M ago
ABUS
Arbutus Biopharma reports FY22 EPS (46c), consensus (45c)
The FlyArbutus Biopharma reports FY22 EPS (46c), consensus (45c)
3M ago
ABUS
Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
The FlyStreet Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
3M ago
ABUS
ALNY
SVB downgrades Moderna to Underperform as COVID boom reverses
The FlySVB downgrades Moderna to Underperform as COVID boom reverses
3M ago
ABUS
ALNY
Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
Press ReleasesArbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update
3M ago
ABUS
Arbutus Biopharma management to meet with Piper Sandler
The FlyArbutus Biopharma management to meet with Piper Sandler
3M ago
ABUS
Arbutus Biopharma management to meet with Piper Sandler
The FlyArbutus Biopharma management to meet with Piper Sandler
3M ago
ABUS
Arbutus to Participate in Three Upcoming Investor Conferences
Press ReleasesArbutus to Participate in Three Upcoming Investor Conferences
4M ago
ABUS
iosandroid
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert CenterEtf Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksCareersContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.